Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805457 | 0.74 | SMPD3 (0.55) | NPSR1LMNAKDM4EHTTIRAK4 | |
| SCHEMBL31294093 | 0.69 | KDM4E (0.67) | KDM4EIRAK4 | |
| SCHEMBL22792158 | 0.68 | SMPD3 (0.55) | NPSR1LMNAKDM4EHTTIRAK4 | |
| SCHEMBL30579408 | 0.68 | SMPD3 (0.55) | NPSR1LMNAKDM4EHTTIRAK4 | |
| SCHEMBL22792265 | 0.67 | SMPD3 (0.50) | NPSR1LMNAKDM4EHTTIRAK4 | |
| SCHEMBL30579401 | 0.65 | SMPD3 (0.47) | NPSR1LMNAKDM4EHTTIRAK4 | |
| SCHEMBL1243349 | 0.65 | SMPD3 (0.51) | NPSR1LMNAKDM4EIRAK4SMPD3 | |
| SCHEMBL29518379 | 0.65 | SMPD3 (0.51) | LMNAKDM4EHTTIRAK4SMPD3 | |
| SCHEMBL15312076 | 0.64 | NPSR1 (0.51) | NPSR1KDM4EALOX15HTTPOLB | |
| SCHEMBL13779362 | 0.64 | KDM4E (0.88) | NPSR1LMNADRD4DRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059690-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2024-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059690-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | SIGMAR1, OPRD1, P2RX3 | NPSR1 421/4885LMNA 3776/4885DRD4 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.